Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer
Your Article Summary
See Latest ArticlesPulmonary arterial hypertension associated with interferon beta treatment for multiple sclerosis: a case report
Multiple Sclerosis, 06/01/09
Ledinek AH et al. - A 23-year-old woman with multiple sclerosis developed respiratory symptoms 3 years after introduction of interferon beta-1b. The diagnosis of pulmonary arterial hypertension (PAH) was established. The patient partially responded to sildenafil and bosetan treatment. This is the first report of PAH, associated with interferon beta therapy. As shown in experimental models, interferon treatment can induce PAH by stimulation of thromboxane cascade and secretion of various inflammatory mediators.
Today in CV/Thromboembolic...keeping you current
Receive free subspecialty "5-minute updates" via email
The clinical course of pulmonary embolism patients anticoagulated for 1 year: results of a prospective, observational, cohort study
Journal of Thrombosis and Haemostasis, 12/18/09
Volumetric or time-based capnography for excluding pulmonary embolism in outpatients
Journal of Thrombosis and Haemostasis, 12/18/09
Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil
Rheumatology, 12/18/09
Sponsor
Article Search
Sponsor
Sponsor